Market Research Logo

Editas Medicine Inc (EDIT) - Financial and Strategic SWOT Analysis Review

Editas Medicine Inc (EDIT) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a discovery stage biotechnology company that develops genome level treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The CRISPR technology employs a protein RNA complex that targets specific stretches of genetic code and enables editing of DNA at accurate locations in the human genome. Editas Medicine’s pre-clinical pipeline spans investigational candidates for the treatment of genetic and infectious diseases of eye, hematologic diseases, cancer, and diseases of muscle, lung and liver. The company works in collaboration with various biotechnology and pharmaceutical companies and research institutions. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.

Editas Medicine Inc Key Recent Developments

Aug 09,2017: Editas Medicine Announces Second Quarter 2017 Results and Update
Aug 09,2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
May 31,2017: Editas Medicine Names Andrew Hirsch to Board of Directors
May 15,2017: Editas Medicine Announces First Quarter 2017 Results and Update
May 13,2017: Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company 6
Editas Medicine Inc - Key Facts 6
Editas Medicine Inc - Key Employees 7
Editas Medicine Inc - Key Employee Biographies 8
Editas Medicine Inc - Major Products and Services 9
Editas Medicine Inc - History 10
Editas Medicine Inc - Company Statement 11
Editas Medicine Inc - Locations And Subsidiaries 17
Head Office 17
Section 2 – Company Analysis 18
Editas Medicine Inc - Business Description 18
Editas Medicine Inc - Corporate Strategy 19
Editas Medicine Inc - SWOT Analysis 20
SWOT Analysis - Overview 20
Editas Medicine Inc - Strengths 20
Editas Medicine Inc - Weaknesses 21
Editas Medicine Inc - Opportunities 22
Editas Medicine Inc - Threats 23
Editas Medicine Inc - Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Editas Medicine Inc, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 35
Aug 09, 2017: Editas Medicine Announces Second Quarter 2017 Results and Update 35
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 37
May 31, 2017: Editas Medicine Names Andrew Hirsch to Board of Directors 38
May 15, 2017: Editas Medicine Announces First Quarter 2017 Results and Update 39
May 13, 2017: Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas 41
Apr 24, 2017: Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting 42
Mar 07, 2017: Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update 44
Mar 03, 2017: Editas Medicine Announces Departure of Chief Operating Officer 46
Nov 07, 2016: Editas Medicine Announces Third Quarter 2016 Results and Update 47
Oct 17, 2016: Editas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 2016 49
Section 6 – Appendix 50
Methodology 50
Ratio Definitions 50
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Tables
Editas Medicine Inc, Key Facts 6
Editas Medicine Inc, Key Employees 7
Editas Medicine Inc, Key Employee Biographies 8
Editas Medicine Inc, Major Products and Services 9
Editas Medicine Inc, History 10
Editas Medicine Inc, Key Competitors 24
Editas Medicine Inc, Ratios based on current share price 25
Editas Medicine Inc, Annual Ratios 26
Editas Medicine Inc, Annual Ratios (Cont...1) 27
Editas Medicine Inc, Interim Ratios 29
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Editas Medicine Inc, Recent Deals Summary 33
Currency Codes 50
Capital Market Ratios 50
Equity Ratios 51
Profitability Ratios 51
Cost Ratios 52
Liquidity Ratios 52
Leverage Ratios 53
Efficiency Ratios 53
List of Figures
Editas Medicine Inc, Performance Chart (2013 - 2016) 28
Editas Medicine Inc, Ratio Charts 30
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 32

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report